Summary:

As a general rule, successful antineoplastic treatments induce an antitumor immune response, even if they were initially designed to target cancer cell–autonomous pathways. In this issue of Blood Cancer Discovery, Gulla and colleagues reveal that the proteasome inhibitor bortezomib induces immunogenic stress and death in multiple myeloma cells, thus explaining its therapeutic efficacy.

See related article by Gulla et al., p. 468.

You do not currently have access to this content.